Neuralstem Inc

Find Ratings Reports
CUR : NASDAQ : Health Care
$5.28 -0.22 | -4.0%
Today's Range: 5.2 - 5.5
Avg. Daily Volume: 355300.0
03/30/17 - 4:00 PM ET

Financial Analysis


NEURALSTEM INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. NEURALSTEM INC has weak liquidity. Currently, the Quick Ratio is 0.73 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 142.51% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)0.00.0
EBITDA ($mil)-4.82-5.11
EBIT ($mil)-4.92-5.2
Net Income ($mil)-5.22-5.64


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)5.6818.15
Total Assets ($mil)8.4521.14
Total Debt ($mil)4.839.08
Equity ($mil)-3.798.9


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin-160633.33-170300.0
EBITDA Margin-160633.33-170300.0
Operating Margin-163900.0-173233.33
Sales Turnover0.00.0
Return on Assets-241.91-102.36
Return on Equity0.0-243.08
Debt Q3 FY16 Q3 FY15
Current Ratio0.852.62
Debt/Capital4.630.51
Interest Expense0.240.46
Interest Coverage-20.4-11.2


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)8.837.06
Div / share0.00.0
EPS-0.65-0.78
Book value / share-0.431.26
Institutional Own % n/a n/a
Avg Daily Volume449382.0517047.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CUR NM Peers 38.87   CUR NM Peers 22.28

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CUR's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CUR's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CUR NM Peers 58.77   CUR NA Peers 0.49

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

CUR's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CUR NM Peers 11.85   CUR 12.50 Peers 165.61

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CUR's P/B is negative making this valuation measure meaningless.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CUR is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CUR 4813.71 Peers 256.31   CUR -23.08 Peers 609.16

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CUR is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CUR significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades